| Title | Nebivolol increases ANP plasma levels in hypertensive patients | |
| Authors | P.C. Papadopoulos¹, B. Kokkas², P. Kotridis¹, G. Aidonidis¹, V. Koutsimanis¹, D. Karnaras¹, I. Vogiatzis¹, G. Dadoush¹, M. Karamouzis³, A. Kouyoumtzis², G. Sakantamis¹, D.I. Hatseras⁴ and C.L. Papadopoulos¹
Departments of 1. Cardiology 2nd , 2. Pharmacology and 3. Biochemistry, Medical School, Aristotle University of Thessaloniki, Greece 4. Department of Cardiology, Medical School, Demokritus University of Thrace, Greece |
|
| Citation | Papadopoulos, P.C., Kokkas, B., Kotridis, P., Aidonidis, G., Koutsimanis, V. et al: Nebivolol increases ANP plasma levels in hypertensive patients, Epitheorese Klin. Farmakol. Farmakokinet. 20(2): 281-282 (2006) | |
| Publication Date | Accepted for publication: 19-20 May 2006 | |
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Nebivolol, ANP, hypertension, β-adrenergic blockers. | |
| Other Terms | review article | |
| Summary | The aim of this study was to evaluate the medium term effects of nebivolol, a highly selective blocker of β1-adrnenergic receptors which in addition stimulates the release of nitric oxide (NO), on atrial natriuretic peptide (ANP) levels in 25 patients with moderate uncomplicated essential hypertension. The drug was given orally for 30 days. The daily dose was 5 mg once every morning. Quantitative determination of human ANP was made by radioimmunoassay procedure (RIA). At the end of this clinical trial, mean plasma levels of ANP rose after treatment by 10.99% (from 42.74 μg/ml to 47.44 μg/ml) while both systolic SBP) and diastolic (DBP) blood (pressure as well as left cardiac cavities diameters were decreased in a statistically significant way. The ratio ANP/SBP was also increased by 44.7% in a statistically significant way and that was the more important and essential finding. These findings provide strong indications which are supported by several previous trials, that the increase in plasma ANP following the administration of β-adrenergic blockers to hypertensive patients is a primary effect of beta blockade and not a mechanical one secondary to a negative inotropic action on the left ventricle and contributes to the antihypertensive effect. | |
| References | 1. Papadopoulos C.L, Kokkas B, Kotridis P, et al.: The effect of β1-blocker bisoprolol on atrial natriuretic peptide plasma levels in hypertensive patients. Intern. J. Angiology 4: 165-168 (1995)
2. Papadopoulos C.L, Kokkas B, Kotridis P, et al.: The effect of β1-blocker / β2-agonist celiprolol on atrial natriuretic peptide plasma levels in hypertensive patients. Cardiovasc. Drugs Ther. 12: 345-346 (1998) 3. Papadopoulos C.L, Kokkas B, Anogiannakis G.: Beta blockers and atrial natriuretic peptide (ANP) in hypertension. Intern. J. Immunopathol. Pharmacol. 13: 107-110 (2000) 4. Papadopoulos C.L., Kokkas B.A.: Atrial natriuretic peptide contributes to the antihypertensive action of many drugs. Eur. J. Drug Metabol. Pharmacokinet. 28: 55-58 (2003) 5. VanLommen G., DeBruyn M., Schroven M.: Synthesis and pharmacological properties of nebivolol, a new antihypertensive compound. J. Pharm. Belg. 45: 355-360 (1990) 6. Bowman A., Chen C., Ford G.: Nitric oxide mediated venodilator effects of Nebivolol. Br. J. Clin. Pharmacol. 38: 199-204 (1994) 7. Hama J., Nagata S., Takenaka T., et al.: Atrial natriuretic peptide and antihypertensive action due to beta – blockade in essential hypertensive patients. Angiology 46: 511-516 (1995) 8. Kokkas B., Kotridis P., Karamouzis M., et al.: Plasma atrial natriuretic peptide levels in essential hypertension after treatment with verapamil. Eur. J. Drug Metab. Pharmacokinet. 27: 45-48 (2002) 9. Iwasaki T., Niwa A., Shinoda T., et al.: Effects of calcium antagonists and nitroglycerin on atrial natriuretic peptide in normal subjects and patients with essential hypertension. Angiology 40: 24-28 (1989) 10. Hollenberg M., Plum J., Heering P., et al.: Influence of betaxolol on renal function and atrial natriuretic peptide in essential hypertension. J. Hypertension 9: 819-824 (1991) 11. Geller D., Currie M., Wakitani K.: Atriopeptides. Biochem. Biophys. Res. Commun. 120: 333-338 (1984) 12. Rosmalen F., Horman J., Tan A., et al.: A sensitive radio-immunoassay of atrial natriuretic peptide in human plasma; some guidelines for clinical applications. Z. Kardiol. 77 (Suppl.2): 20-25 (1988) 13. Karamouzis M., Mandroukas K., Deligiannis D., et al. Changes in atrial natriuretic peptide (a-ANP) in long distance swimmers. Clin. Chem. Enzym. Comms. 6: 191-195 (1994) |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2006 – ANNUAL SUBSCRIPTION 2006 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|